nϭ1520) and 192 for BevacizumabϩInterferon (B, nϭ171). Approximately one quarter of patients were lost in the second month of treatment (Tϭ39%; Soϭ36%, Pϭ35%; Eϭ28%; Suϭ25%; Bϭ21%). CONCLUSIONS: Persistence in first line treatment of mRCC is very low. Best persistence can be observed for BevacizumabϩInterferon which is the only intravenous treatment in this indication. Further research may be required to evaluate if the increased use of oral treatments has a negative impact on patient adherence and if adequate measures are required to improve this situation.
PCN110 DIFFERENCES IN HEALTH-RELATED QUALITY OF LIFE BETWEEN CHILDREN TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) ON DANA FARBER CANCER INSTITUTE (DFCI) PROTOCOLS
Rae CS 1 , Horsman JR 2 , Furlong W 2 , Silverman LB 3 , Sallan SE 3 , Athale U 1 , Pullenayegum E 1 , Barr RD 1 1 McMaster University, Hamilton, ON, Canada, 2 Health Utilities Inc., Dundas, ON, Canada, 3 Harvard Medical School, Boston, MA, USA OBJECTIVES: To identify differences in health-related quality of life (HRQL) between 2 consecutive Dana Farber Cancer Institute (DFCI) protocols to treat acute lymphoblastic leukemia (ALL) diagnosed during childhood. METHODS: Children diagnosed with standard and high risk ALL and treated according to DFCI protocol 95-001 or 00-001 at 5 and 9 Centres, respectively, in Canada and the USA were eligible for study. Parents of patients completed Health Utilities Index (HUI) questionnaire assessments during each of 4 major phases of therapy (induction of remission, central nervous system-directed treatment, intensification, continuation), and at 2 years post-treatment. Differences between protocols in mean HRQL scores for each phase were assessed using a t-test for independent groups. Qualityadjusted life years (QALYs), based on mean HRQL scores for and duration of each protocol phase, were used to determine the importance of differences. RESULTS: A total of 381 (00-001) and 375 (95-001) patients were assessed. There were no differences between protocols in the distribution of patients by gender (pϭ0.66) or risk group (pϭ0.56). During the first phase of treatment, the mean HRQL score of 00-01 patients (0.75) was importantly better (diffϭ0.18, pϭ0.03) than 95-001 patients (0.67). Differences during this phase were in the attributes of dexterity (pϭ0.03) and emotion (pϭ0.009). There were no significant differences (pՆ0.05) between groups during any of the other phases or post-treatment. Over the 5 year period, 00-001 patients experienced 0.06 greater QALYs, or 3 quality-adjusted life weeks (QALW), than 95-001 patients. CONCLUSIONS: Assuming similar or reduced relapse and mortality rates, 3 QALW represents an important gain in HRQL for the more recent DFCI 00-01 protocol. 
PCN111 THE VALUE OF PERSONALIZING MEDICINE: MEDICAL ONCOLOGISTS' AND PATIENTS' PERSPECTIVES ON GENOMIC TESTING OF BREAST TUMOURS IN CHEMOTHERAPY TREATMENT DECISIONS

OBJECTIVES:
The benefit of adjuvant chemotherapy for early-stage breast cancer (BrCa) patients depends on baseline recurrence risk. Gene expression profiling (GEP) of tumours informs baseline risk prediction, potentially reducing unnecessary treatment and health care costs. Limited evidence exists on its clinical utility; we explored patients' and oncologists' perspectives on GEP in chemotherapy decisions. METHODS: We conducted individual interviews with medical oncologists (nϭ10), plus focus groups and individual interviews with BrCa patients (nϭ20) from Ontario, Canada. BrCa patients who underwent genomic testing ('On-cotypeDx'), were recruited through oncology clinics from two academic hospitals in the Greater Toronto Area. Medical oncologists were recruited through participating oncology clinics, professional advertisements and referrals from the research team. Data were analyzed using interpretative qualitative methods, including content analysis, qualitative description and constant comparison techniques. RESULTS: Patients and oncologists valued GEP as an additional decision-support tool, complementing existing clinical indicators, though perceived utility varied between patients and oncologists. Patients valued the test highly, suggesting it was one of the primary determinants of their treatment decision. All patients followed the course of action their results suggested. Patients with intermediate scores often used the results to reinforce their pre-existing treatment preferences. Oncologists were mixed about the test's utility. Some considered it another tool supporting their approach to risk assessments; others used it more definitively to resolve their uncertainty. Oncologists explained the test's contribution to decision-making but remained uncertain about patients' understanding and expectations of the test. Some raised concerns about the variability of its use and interpretation within their medical community. CONCLUSIONS: Patients and oncologists valued the test, often using it as a primary determinant in their treatment decision, despite oncologists' concerns about its technical limitations and patients' limited understanding. Results identify need for informational decision aids and practice guidelines to support patient understanding and standardized application of the test.
PCN112
CHARACTERISTICS OF CANCER PATIENTS WHO SEEK CYTOSTATIC THERAPY IN KOREA: A PILOT STUDY
OBJECTIVES: FDA and EMA have created guidelines for PRO label claims. However, there have been few PRO-based label claims in oncology (Gnanasakthy, et al., 2012) since the release of the FDA guidelines. The objective of this research was to explore factors that might predict regulatory success for PROs. We developed a regulatory success gradient, and used factors based on literature review, expert interviews, and the FDA Guidances to predict success. METHODS: Using a case-control approach, 10 oncology medications with PRO labels came from two sources: 1) a review of PROs in oncology labels (Gondek et al, 2007) , and 2) a proprietary database (http://www.mapi-prolabels.org/) containing a list of PRO-based labels. Six controls were oncology medications with the same indication and mechanism of action, but without PRO data in the label. Regulatory success was defined from none (no PRO in the label), through minimal, mild, and moderate, to great success (PRO labeling in the indication section). Independent factors, derived from literature review, expert interviews, and the PRO Guidances, possibly related to regulatory success included conceptual fit, study quality, conformity to PRO Guidance (content validity), psychometrics score, and other PRO characteristics, were evaluated. RESULTS: No medication achieved great PRO labeling success. Only three medications achieved moderate regulatory success, seven achieved mild, and five achieved minimal success. None of the factors identified as potentially related to regulatory success were significantly correlated with it (Spearman correlations): Other PRO Characteristics (0.33), Conceptual Fit (0.09), Study Quality (-0.13), Psychometrics (-0.18), and Conformity to the PRO Guidance (0-0.02). CONCLUSIONS: Despite widespread use of PROs in oncology, very few labels actually include PRO-based results, and furthermore, no medications achieved great success and only three moderate success in labeling. Based on our regulatory success gradient, driving factors leading to regulatory success have yet to be identified.
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QUALITY OF LIFE IN LUNG CANCER PATIENTS DURING ADJUVANT OR PALLIATIVE CHEMOTHERAPY
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